Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Escient Pharmaceuticals, founded in 2018 and headquartered in San Diego, California, is a clinical-stage pharmaceutical company specializing in the development of targeted small-molecule therapeutics. The company focuses on creating G protein-coupled receptor (GPCR)-targeted drugs to address unmet medical needs across various therapeutic indications. Escient's product pipeline includes small molecule antagonists for treating mast cell-mediated disorders and cholestatic pruritus.
Since its inception, Escient Pharmaceuticals has successfully raised a total of $237.5 million in funding, demonstrating significant investor interest in its innovative approach to drug development. The company's focus on GPCR-targeted therapies positions it in a promising niche within the pharmaceutical industry.
It's important to note that in April 2024, Escient Pharmaceuticals was acquired by Incyte, a major development in the company's trajectory. This acquisition likely impacts any potential plans for an initial public offering (IPO) that Escient may have had.
Given the recent acquisition, we do not have any current information or reports regarding Escient Pharmaceuticals' IPO prospects. The company's future direction and potential public offering plans will likely be influenced by its new parent company, Incyte. Investors interested in Escient Pharmaceuticals should monitor developments related to Incyte for potential opportunities.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Escient Pharmaceuticals' IPO prospects remain uncertain, investors eager to explore opportunities in the pharmaceutical sector don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the pharmaceutical and biotech industries, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from the growth of innovative companies like Escient Pharmaceuticals before they hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
